Back to top
more

Champions Oncology (CSBR)

(Delayed Data from NSDQ)

$5.00 USD

5.00
1,901

+0.01 (0.10%)

Updated Sep 1, 2026 03:50 PM ET

After-Market: $4.98 -0.02 (-0.40%) 5:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 248)

Industry: Medical - Drugs

Zacks News

Zacks Equity Research

5 Best Biotech Stocks to Buy In October

Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October

    Zacks Equity Research

    Looking for a Top Momentum Pick? Why Champions Oncology (CSBR) is a Great Choice

    Does Champions Oncology (CSBR) have what it takes to be a top stock pick for momentum investors? Let's find out.

      Zacks Equity Research

      Zacks.com highlights: Champions Oncology, STAAR Surgical, Boingo Wireless, Verso and BioSpecifics Technologies

      Zacks.com highlights: Champions Oncology, STAAR Surgical, Boingo Wireless, Verso and BioSpecifics Technologies

        Zacks Equity Research

        5 Stocks With Recent Price Strength to Strengthen Portfolio

        Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

          Zacks Equity Research

          Champions Oncology (CSBR) Q1 Earnings Preview: How Are Events Shaping Up?

          Champions Oncology (CSBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

            Zacks Equity Research

            Zacks.com highlights: Safeguard Scientifics, Exantas Capital, Champions Oncology, Stars Group and GDS Holdings

            Zacks.com highlights: Safeguard Scientifics, Exantas Capital, Champions Oncology, Stars Group and GDS Holdings

              Zacks Equity Research

              5 Stocks to Buy as New Analysts Show Interest

              Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.